BTIG Reiterates Buy on Innate Pharma, Maintains $9 Price Target
BTIG analyst Jeet Mukherjee reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $9 price target.
Stocks · News reference
Innate Pharma H1 EPS $(0.24) Misses $(0.16) Estimate, Sales $6.583M Miss $9.100M Estimate
Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.16) by 50 percent. This is a 14.29 percent increase over losses of $(0.28) per share from the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Innate Pharma H1 2026 Earnings Call Transcript
Innate Pharma (NASDAQ:IPHA) held its quarterly earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and
Earnings Scheduled For September 17, 2026
Companies Reporting Before The Bell • 111 (NASDAQ:YI) is projected to report earnings for its second quarter. • Innate Pharma (NASDAQ:IPHA) is projected to report quarterly loss at $0.16 per share on revenue of $9.10